415979-31-6Relevant articles and documents
BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
-
Paragraph 0984-0985, (2019/10/23)
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS
-
Page/Page column 68-69, (2008/06/13)
A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias
-
, (2008/06/13)
There is provided compounds of formula (I), wherein R1, R2 and Ra to Rb have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and v
